These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25636461)

  • 1. Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 system.
    Ishibashi Y; Matsui T; Fukami K; Ueda S; Okuda S; Yamagishi S
    Thromb Res; 2015 Apr; 135(4):770-3. PubMed ID: 25636461
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban.
    Tripodi A; Martinelli I; Chantarangkul V; Clerici M; Artoni A; Passamonti S; Peyvandi F
    Int J Hematol; 2016 Feb; 103(2):165-72. PubMed ID: 26586461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal dosing of rivaroxaban is undefined.
    Moore TJ
    BMJ; 2016 Oct; 355():i5549. PubMed ID: 27756735
    [No Abstract]   [Full Text] [Related]  

  • 4. Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism.
    Dittmeier M; Kraft P; Schuhmann MK; Fluri F; Kleinschnitz C
    Thromb Haemost; 2016 Apr; 115(4):835-43. PubMed ID: 26489881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia.
    Imano H; Kato R; Tanikawa S; Yoshimura F; Nomura A; Ijiri Y; Yamaguchi T; Izumi Y; Yoshiyama M; Hayashi T
    J Pharmacol Sci; 2018 Jul; 137(3):274-282. PubMed ID: 30055890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rivaroxaban starter packs on emergency department throughput.
    Ayers GT; D'Amico PhD F; Farrah RM; Klatt PM; Baumgartner MA
    Am J Emerg Med; 2018 Sep; 36(9):1698-1699. PubMed ID: 29429797
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of rivaroxaban in left ventricular thrombi.
    Abdelnaby M; Almaghraby A; Abdelkarim O; Saleh Y; Hammad B; Badran H
    Anatol J Cardiol; 2019 Jan; 21(1):47-50. PubMed ID: 30587707
    [No Abstract]   [Full Text] [Related]  

  • 8. Rivaroxaban for cancer-associated cardiac thrombosis.
    Di Nisio M; Carella C; Natoli C; Porreca E; De Tursi M
    Am J Med; 2015 Oct; 128(10):e43-4. PubMed ID: 26071831
    [No Abstract]   [Full Text] [Related]  

  • 9. The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction.
    Bode MF; Auriemma AC; Grover SP; Hisada Y; Rennie A; Bode WD; Vora R; Subramaniam S; Cooley B; Andrade-Gordon P; Antoniak S; Mackman N
    Thromb Res; 2018 Jul; 167():128-134. PubMed ID: 29843086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clear Instructions and Patient Education Key for Xarelto.
    Shastay A
    Home Healthc Now; 2020; 38(4):225-226. PubMed ID: 32618785
    [No Abstract]   [Full Text] [Related]  

  • 11. Rivaroxaban for thromboprophylaxis in a patient receiving electroconvulsive therapy.
    Shuman M; Hieber R; Moss L; Patel D
    J ECT; 2015 Mar; 31(1):e19-20. PubMed ID: 25587812
    [No Abstract]   [Full Text] [Related]  

  • 12. [CHANGE OF ANTICOAGULANT EFFECT OF RIVAROXABAN DURING A DAY].
    Gel'tser IV; Smirnova OA; Matvienko OY; Golovina OG; Papayan LP
    Vestn Khir Im I I Grek; 2015; 174(4):77-9. PubMed ID: 26601525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban for the treatment of cerebral venous thrombosis.
    Mutgi SA; Grose NA; Behrouz R
    Int J Stroke; 2015 Oct; 10 Suppl A100():167-8. PubMed ID: 26502976
    [No Abstract]   [Full Text] [Related]  

  • 14. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.
    Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
    Biochem Biophys Res Commun; 2010 Jul; 398(2):326-30. PubMed ID: 20599709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral lung transplantation in a patient receiving rivaroxaban anticoagulation.
    Renner TA; Zalunardo MP; Weder W; Spahn DR
    J Cardiothorac Vasc Anesth; 2015; 29(3):723-6. PubMed ID: 25440624
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
    Barón-Esquivias G; Fernández-Avilés F; Atienza F; Pastor Pueyo P; Toro R; Sanmartín Fernández M
    Expert Rev Cardiovasc Ther; 2015 Apr; 13(4):341-53. PubMed ID: 25797900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
    Farag M; Gorog DA
    Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of Extensive Coronary Thrombosis under Rivaroxaban Treatment.
    Yuksel M; Yildiz A; Tapan U; Ertas F; Alan S
    Arq Bras Cardiol; 2015 Dec; 105(6):642-6. PubMed ID: 26761372
    [No Abstract]   [Full Text] [Related]  

  • 19. Recurrent deep vein thrombosis with rivaroxaban in a patient with metastatic testicular cancer.
    Eid TJ; Kalkat B; Shah SA
    J Pharm Pract; 2015 Jun; 28(3):233. PubMed ID: 25979903
    [No Abstract]   [Full Text] [Related]  

  • 20. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression.
    Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S
    Horm Metab Res; 2012 Nov; 44(12):891-5. PubMed ID: 22864903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.